valu usd unless otherwis note
revenu line guidanc
view expect faster tavr sale growth potenti beat-
and-rais scenario could mitig weak ew share
follow anoth quarter tavr sale fell short consensu
albeit off-set better expect growth shv critic
midpoint revenu guidanc margin
consensu impli high-single-digit sequenti tavr sale
growth estim
ww revenu within guidanc fx lower tax rate drove ep
upsid ww revenu y/i cc guidanc
rbce highest revenu growth among
three major geographi europ japan two
rel sale estim product categori tavr miss
shv critic beat ew report low-double-digit tavr
procedur growth europ market share loss
europ year-over-year stabl share q/q tmtt sale
primarili pascal receiv ce mark februari non-gaap ep
guidanc rbce lower tax rate
account ep upsid vs estim higher gross margin
reflect product mix fx-benefit contribut rest
guidanc line estim ew forecast
revenu ep estim
revenu forecast assum ww tavr sale q/
 y/i midpoint rang sequenti growth
necessari achiev rang higher correspond growth
rate q/q reflect benefit partner
data tavr procedur growth manag commentari
suggest immateri contribut sapien ultra
centera physician feedback valv highli
favor manag believ design advanc sapien
necessit extens oper train therefor slower
ew reaffirm revenu guidanc increas ep guidanc
ew forecast ww revenu tavr sale
critic sale forecast increas
function strong contribut casm
transact close tmtt sale guidanc remain
given suppli constraint cardioband sale come
mostli pascal non-gaap ep guidanc increas
less beat manag project higher
spend level remaind revis estim
increas base higher sale growth estim
light better expect result
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
ew remain attract multi-year growth stori large-
cap med-tech view believ ew deliv
revenu compound-annual-growth-rate next three year
growth rate large-cap compani coverag
manag project ww tavr market
growth driver includ continu
penetr intermediate-risk sever symptomat aortic
stenosi patient expans low-risk popul
onward potenti approv asymptomat
patient basi early-tavr trial improv
patient awar tavr time
manag set realist revenu forecast ew
project total revenu growth tavr
resembl initi guidanc despit competit
price reimburs pressur demonstr
underli strength ew tavr franchis ew also
expect sale contribut transcathet
mitral tricuspid therapi tmtt
tmtt pipelin advanc pascal two separ
trial end primari secondari
deliv transsept also enter trial ew
plan move forward trial devic treat
tricuspid regurgit cardioband pascal forma
spacer three candid content
ew forecast tmtt market believ
variou therapi option compani develop
yield least market share impli
annual sale given size market opportun
inher complex treat mitral valv diseas
room multipl compani flourish view
bloomberg capit market estim upside/downside/target
dcf model yield base case price target key
assumpt follow revenu compound-annual-growth-rate
driven double-digit growth tavr/
mitral franchis mid-single-digit growth two
product categori surgic valv critic ebit
margin tax rate
forecast period cash flow dcf
model discount use wacc
upsid scenario valu assum low-double-digit
revenu growth compound-annual-growth-rate driven
expans moder aortic stenosi asymptomat
along meaning revenu contribut
downsid scenario valu assum mid-single-
digit tavr revenu growth due slower adopt among
intermediate-risk low-risk patient stronger competit
slower expect progress
dcf model yield base case price target key assumpt follow
revenu growth compound-annual-growth-rate driven double-digit growth tavr/
mitral franchis mid-single-digit growth two product categori surgic
valv critic ebit margin tax rate
forecast period cash flow dcf model discount use wacc
price target support outperform rate
risk rate price target
risk price target rate includ limit increas competit
market opportun currenc litig reimburs clinic trial risk
edward lifesci global player product technolog design treat
cardiovascular diseas compani focus specif cardiovascular opportun
includ heart valv diseas critic care technolog peripher vascular diseas
